Marathon Trading Investment Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.7M Buy
+33,500
New +$1.56M 0.05% 68
2025
Q2
Sell
-3,300
Closed -$93.6K 341
2025
Q1
$93.6K Buy
3,300
+1,800
+120% +$63.9K 0.01% 274
2024
Q4
$62.4K Sell
1,500
-3,400
-69% -$163K ﹤0.01% 263
2024
Q3
$327K Sell
4,900
-1,200
-20% -$110K 0.03% 174
2024
Q2
$724K Sell
6,100
-2,600
-30% -$329K 0.05% 118
2024
Q1
$927K Buy
8,700
+7,200
+480% +$726K 0.07% 117
2023
Q4
$149K Sell
1,500
-100
-6% -$8.41K 0.01% 284
2023
Q3
$165K Sell
1,600
-1,100
-41% -$123K 0.01% 234
2023
Q2
$328K Buy
+2,700
New +$360K 0.03% 153
2023
Q1
Sell
-800
Closed -$144K 308
2022
Q4
$144K Sell
800
-2,100
-72% -$343K 0.02% 197
2022
Q3
$343K Buy
+2,900
New +$440K 0.03% 181
2020
Q4
Sell
-5,800
Closed -$410K 377
2020
Q3
$410K Buy
+5,800
New +$404K 0.03% 207

Other funds holding MRNA

Marathon Trading Investment Management's MRNA Position: Q1 2026 in Review

Marathon Trading Investment Management reduced its Moderna (MRNA) stake by 99% in Q1 2026, selling an estimated $1.59M and leaving 203 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #259.

Marathon Trading Investment Management first reported a position in MRNA in Q4 2020 and has held it in 11 quarters since. The position peaked at $2.84M in Q4 2023. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Marathon Trading Investment Management held 203 shares of Moderna worth $10.3K as of Q1 2026.
  • Marathon Trading Investment Management sold 34,074 Moderna shares in Q1 2026, an estimated $1.59M.
  • Moderna made up ﹤0.01% of Marathon Trading Investment Management's portfolio in Q1 2026, its #259 holding.
  • Marathon Trading Investment Management first reported a position in Moderna in Q4 2020 and has held it in 11 quarters since.
  • Marathon Trading Investment Management's Moderna position peaked at $2.84M in Q4 2023.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Marathon Trading Investment Management's 13F filing for Q1 2026, filed 14 May 2026.